An investigation on behalf of investors of Intrexon Corp (NYSE: XON) shares over potential securities laws violations by Intrexon Corp and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Intrexon Corp (NYSE: XON) concerning whether a series of statements by Intrexon regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Germantown, MD based Intrexon Corporation operates in the synthetic biology field in the United States.I ntrexon Corp reported that its annual Total Revenue rose from$173.60 million in 2015 to $190.92 million in 2016 to while its Net Loss increased from $84.49 million in 2015 to $186.61 million in 2016.

On August 9, 2018, Intrexon Corporation filed an 8-K announcing that it would restate the unaudited interim consolidated financial statements included in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2018. The restatement is the result of incorrect application of certain aspects of Accounting Standards Codification Topic 606, Revenue from Contracts with Customers. According to the Company, 'these errors have resulted in an overstatement of deferred revenue and accumulated deficit by approximately $67 million as of the adoption date...'

Then on August 13, 2018, Intrexon Corporation filed an amended and restated 10-Q for the quarter ended March 31, 2018.